From Cure:
Cabometyx (cabozantinib) significantly reduced the risk of death by 34 percent compared with Afinitor (everolimus) among patients with previously treated advanced renal cell carcinoma (RCC), according to results from the METEOR trial. These phase 3 findings were presented at the 2016 Annual Meeting of the American Society of Clinical Oncology, a gathering of 30,000 oncology professionals in Chicago. CURE spoke with Jorge Garcia, a medical oncologist at the Cleveland Clinic and one of the researchers on the study about the benefit of Cabometyx and what’s next for the treatment of RCC.
Read the full story.
